Member Info for Laura2022

Our view remains that early monetization and commercialization of each of these programs is more likely to occur with, and would benefit from, the involvement of a partner organisation with significant presence in the relevant market.

Notwithstanding this, in the case of EpiSwitch® SCB, we announced that we will make the test available (on a regular commercial basis) to a select group of veterinarians who will generate real-world utility data that will further validate the test and support any eventual partnership or outlicensing agreement with an organization with presence in the pet healthcare market.

Our aim is to expedite the market readiness of these high-performing tests, and potentially to generate additional funding for the Company. Confidential discussions with third parties about each of EpiSwitch® NST and EpiSwitch® SCB commenced in early 2024 and have continued after the period.

It mentions something in March results about strategic partnerships?

Do you know what this means?

Good to see that the CEO's 10m share options are tied in to the performance of the shares relative to the recent fund raise, as he only benefits if the share price exceeds 9p, and the more the share price exceeds 9p the more he and those who invested in the fund raise stand to gain. Looking more like a partnership deal would benefit all shareholders as well as the CEO.

Would you be happy to outline some of the main parts Trench please ?

I will not get time to watch until tomorrow sadly

Yes Formereasyp

Do u know who this TR1 person is please ?

You never did answer those inconvenient truths GG

Permanent filter

Been a disaster last 3mths (15p to 3.5p) but it looks harsh

Commenting on the results, Dr Jon Burrows, Chief Executive Officer of Oxford BioDynamics, said:

"Following the launch, ahead of schedule, of our EpiSwitch PSE test at the end of last year, we were pleased with the early award of a unique CPT code for reimbursement of the test in the US. It is still early days post-launch, but we believe we have set the right foundations and followed a careful approach to building the market for PSE. We believe this approach is beginning to bear fruit, with over 30 clinics ordering and nine commercial agreements for the sale or distribution of the test signed since the beginning of the financial year.

"We have continued to pursue growth in adoption of our CiRT test during and after the period. Baseline test orders remained stable, and the work done by a refreshed and expanded team in the period is now bringing the test to more US oncologists through our engagement with CMOs at regional hospital groups.

Last month, at the 14th Clinical Biomarkers and Companion Diagnostics World Summit in Boston, OBD presented in a key-note talk the latest real-world evidence from adoption of our commercialy available Checkpoint Inihibitor Response (CiRT) test in the US, including in the PROWES national observational registry study. The Company also shared results of the development and validation of its Hyperprogression Immune Response Test (HiRT

Read it carefully without the negative glasses

Oxford BioDynamics ("OBD" or the "Company" and, together with its subsidiaries, the "Group")

CIRRP Award Update

Oxford, UK - 7 October 2024 - Oxford BioDynamics, Plc (AIM: OBD, the Company), a precision clinical diagnostics company bringing specific and sensitive tests to the practice of medicine based on its EpiSwitch® 3D genomics platform, notes that the UK Cancer Immunotherapy Response Research Platform (CIRRP) funding for biomarker development for cancer immunotherapies has been awarded by the government-run Office for Life Sciences and the Medical Research Council to the MANIFEST consortium led by the Francis Crick Institute.

OBD was part of the EpiSwitch consortium, led by the University of Oxford, and including the University of Birmingham and five NHS Trusts, which was shortlisted for the award.

In its feedback to the EpiSwitch consortium, the Panel explained its decision: "The Panel agreed that the application was based on an interesting technology that was already routinely used in the USA and in private UK clinics. However, Members agreed that while this was an excellent collaboration between a diagnostics company and a single [sic] academic group, it didn't fulfil the expectations of the Opportunity to build a legacy UK-wide consortium to deliver research into cancer immunotherapy.

Members agreed that the application concentrated on moving the current technology into standard practice within the NHS and would have been strengthened by providing greater detail on new tests to be developed with a focus on mechanistic molecular insight as well as correlating the blood work back to tumour data."

Government will provide funding for a £120 blood test that has the potential to detect the 12 most common forms of cancer before symptoms develop.

The Mionco screening can identify 50 cancers before producing a false positive and is a form of the PCR test used during the Covid pandemic, according to the scientists involved in its development.

It checks the 12 most common forms of the disease: lung, breast, prostate, pancreatic, colorectal, ovarian, liver, brain, oesophageal, bladder, bone and soft tissue sarcoma, and gastric.

Looking good

Off topic

Beaten down but unfairly .OBD are part of £100mln+ cancer detection government programme mentioned in BBC on weekend

Kingh

Pipeline (excluding bio stats) now over £1.7mln mentioned towards middle of annual report

I assume as that was written in June that it will be higher

Success in any of these programmes has the potential to yield significant benefits to pharma in clinical trials, regulatory clearance, pricing and competitive positioning of their drugs. ANGLE is working to secure multiple contracts of a similar structure with large pharma to maximise the number of major revenue opportunities. Prioritising investment towards growth of the large pharma strategy and reducing investment in the products side is intended to maximise ANGLE's commercial opportunity and is now anticipated to deliver cashflow positive trading in the second half of 2026; and the Company is funded to execute on this plan

With regard to the main focus of the CIRRP program, having already successfully completed the stages of biomarker discovery and translation to clinical practice in immuno-oncology, our main objective remains to support the rapid utilization of the accurate and robust CiRT test, in the UK and US."

-Ends-

Thanks Oxmil

Going well

AGL too

0.38p to sell now on a 35/40 spread

Looking like it's going to move

1mln +2mln buyer continues from Friday

Due today according to a Telegram chartist